Ibogaine therapy for substance abuse disorders

Clinical Addiction Psychiatry

Volumn , Issue , 2010, Pages 50-60

  Mash, Deborah C ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880152629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511782107.007     Document Type: Chapter

References (41)

1. Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J. & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal of Addiction,8, 234–42.
2. Barabe, P. (1982). Religion of Eboga or the Bwiti of the Fangs. Medecine Tropicale (Marseilles),42(3), 251–7.
3. Baumann, M. H., Pablo, J. P., Ali, S. F., Rothman, R. B. & Mash, D. C. (2000). Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Annals of the New York Academy of Sciences,914, 354–68.
4. Baumann, M. H., Pablo, J., Ali, S. F., Rothman, R. B. & Mash, D. C. (2001a). Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. Alkaloids: Chemical and Biological Perspectives,56, 79–113.
5. Baumann, M. H., Pablo, J., Ali, S. F., Rothman, R. B. & Mash, D. C. (2001 b). In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. Journal of Pharmacological and Experimental Therapy,297 (2), 531–9.
6. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. & Erbaugh, J. (1961). An interview for measuring depression. A chives of General Psychiatry,4, 561–71.
7. Cappendijk, S. L. T. & Dzoljic, M. R. (1993). Inhibitory effects of ibogaine on cocaine self-administration in rats. European Journal of Pharmacology,241, 261–5.
8. Dackis, C. A. & Gold, M. S. (1985). Pharmacological approaches to cocaine addiction. Journal of Substance Abuse Treatment,2, 139–45.
9. Dzoljic, E. D., Kaplan, C. D. & Dzoljic, M. R. (1988). Eff ect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine dependent rats. Archives Internationales de Pharmacodynamie et de Therapie,294, 64–70.
10. Fermandez, J. W. & Fernendez, R. L. (2001). “Returning to the path”: the use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships. The Alkaloids. Chemistry and Biology,56, 235–47.
11. Gawin, F. H. (1991). Cocaine addiction: psychology and neurophysiology. Science,251, 1580–6.
12. Gawin, F. H. & Ellinwood, E. H. (1988). Cocaine and other stimulants: actions, abuse and treatment. New England Journal of Medicine,318, 1173–82.
13. Glick, S. D., Rossman, K., Steindorf, S., Maisonneuve, I. M. & Carlson, J. N. (1991). effects and aft ereffects of ibogaine on morphine self-administration in rats. European Journal of Pharmacology,195(3), 341–5.
14. Glick, S. D., Rossman, K., Rao, N. C., Maisonneuve, I. M. & Carlson, J. N. (1992). effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology,31, 497–500.
15. Goutarel, R., Gollnhofer, O. & Sillans, R. (1991). Pharmacodynamics and therapeutic applications of iboga and ibogaine. Psychedelic Monographs and Essays,6, 71–111.
16. Hearn, W. L., Mash, D. C., Pablo, J. (1995 a). Pharmacokinetics of ibogaine: analytical method, animal–human comparisons, and the identifi cation of a primary metabolite. Proceedings of the TIAFT-SOFT Joint Congress, October 21–November 4, 1994, ed. V. Spiehler. Ann Arbor, MI: Omnipress, pp. 325–34.
17. Hearn, W. L., Pablo, J., Hime, G. & Mash, D. C. (1995b). Identifi cation and quantitation of ibogaine and an O-demethylated metabolite in brain and biological fl uids using gas chromatography/mass spectrometry. Journal of Analytical Toxicology,19, 427–34.
18. Hoff er, A. & Osmond, H. (1967). The Hallucinogens. New York: Academic Press.
19. James, W. (1890). The Principles of Psychology. New York, NY: Dover, Inc.
20. Kenna, G. A., Nielsen, D. M., Mello, P., Sciesl, A. & Swift, R. M. (2007). Pharmacotherapy of dual substance abuse and dependence. CNS Drugs,21(3), 213–37.
21. Lambert, M. & Heckel, E. (1901). Sur la racine d’iboga et sur l’ibogaine. Comptes Rendus,133, 1236.
22. Martin, W. R. & Jasinski, D. R. (1969). Physiological parameters of morphine dependence in man– tolerance, early abstinence, protracted abstinence. Journal of Psychiatric Research,7, 9–17.
23. Mash, D. C. & Schenk, S. (1996). Preclinical screening of an ibogaine metabolite (noribogaine) on cocaine-induced hyperlocomotion and cocaine self-administration. Society for Neuroscience Abstracts,22, 1929.
24. Mash, D. C., Staley, J. K., Baumann, M. H., Rothman, R. B. & Hearn, W. L. (1995 a). Identifi cation of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Science,57, PL45–50.
25. Mash, D. C., Pablo, J., Staley, J. K. (1995 b). Properties of ibogaine and a principal metabolite 12-hydroxyibogamine at the MK-801 binding site on the NMDA- receptor complex. Neuroscience Letters,192, 53–6.
26. Mash, D. C., Kovera, C. A., Buck, B. E. et al. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences,844, 274–92.
27. Mash, D. C., Kovera, C. A., Pablo, J. (2000). Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary effi cacy measures. Annals of the New York Academy of Sciences,914, 394–401.
28. Mash, D. C., Kovera, C. A., Pablo, J. (2001). Ibogaine in the treatment of heroin withdrawal. Alkaloids: Chemical and Biological Perspectives,56, 155–71.
29. Naranjo, C. (1969). Psychotherapeutic possibilities: new fantasy enhancing drugs. Clinical Toxicology,2, 209–24.
30. Naranjo, C. (1973). The Healing Journey. New Approaches to Consciousness. New York, NY: Pantheon.
31. Obach, R. S., Pablo, J. & Mash, D. C. (1998). Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metabolism and Disposition,25(12), 1359–69.
32. O’Brien, C. P. (1997). A range of research-based pharmacotherapies for addiction. Science,278, 66–9.
33. Pablo, J. & Mash, D. C. (1998). Noribogaine stimulates naloxone-sensitive [35S]GTPgS binding. NeuroReport,9, 109–114.
34. Phisalix, M. C. (1901). Action physiologique de l’ibogaine. Comptes Rendus Societe de Biologie,53, 1077.
35. Popik, P., Layer, R. T. & Sholnick, P. (1995). 100 Years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacological Reviews,47, 235–53.
36. Pouchet, G. & Chevalier, J. (1905). Les nouveaux remedes. Sur l’action pharmacodynamique de l’ibogaine. Bulletin Géneral de Th érapeutique,149, 211.
37. Shepard, S. G. (1994). A preliminary investigation of ibogaine: case reports and recommendations for further study. Journal of Substance Abuse Treatment,11(4), 379–85.
38. Spangler, R., Ho, A., Zhou, Y. (1996). Regulation of kappa opioid receptor mRNA in the rat brain by ‘binge’ pattern cocaine administration and correlation with preprodynorphin mRNA. Brain Research– Molecular Brain Research,38, 71–6.
39. Staley, J. K., Ouyang, Q., Pablo, J. (1996). Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology,127, 10–18.
40. Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. & Kellner, R. (1994). Dose-response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry,51(2), 98–108.
41. Vocci, F. J., Acri, J. & Elkashef, A. (2005). Medication development for addictive disorders: the state of the science. American Journal of Psychiatry,162(8), 1432–40.